Biodextris in the News

Biodextris is recognized by biotech city as one of the canadian organizations in the fight against covid-19

The Biotech City is proud of the efforts of resident companies contributing to the fight against COVID-19:

Nexelis has been granted reference laboratory status by the Bill and Melinda Gates foundation and is collaborating on candidate vaccines.
Corealis Pharma Inc. has developed oral formulations for antivirals and manufactures clinical batches.
Altasciences has completed a Phase I on gimsilumab in SARS-CoV-2 patients.
Biodextris developing a nasal vaccine platform with preclinical activity.
Roche Diagnostics provides instruments and tests to respond to the pandemic.
Bausch Health donates drugs.
CQIB incubator companies are also involved:
Ovensa Inc. is working on siRNA to modulate viral infection and pulmonary fibrosis.
Oligo Medic has adapted to the manufacture of disinfectant gel.
Glycovax Pharma is working on a platform for viral adhesion inhibitors.
IniXium conducts research on the replication of the virus.
ILS Pharmaceutical performs compliance tests for the release of drugs and disinfectant products.

View original post here: